Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
LTRPC7 Double Nickase Plasmid (h): sc-402820-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LTRPC7 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- LTRPC7 Double Nickase Plasmid (h) and LTRPC7 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting TRPM7. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: LTRPC7 Antibody (H-4): sc-271099
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LTRPC7 Double Nickase Plasmid (h) | sc-402820-NIC | 20 µg | $410.00 | |||
LTRPC7 Double Nickase Plasmid (h2) | sc-402820-NIC-2 | 20 µg | $410.00 |
TRPM7 (LTRPC7) encodes a bifunctional ion channel–kinase that mediates Mg2+ and Ca2+ influx while coupling divalent cation homeostasis to serine/threonine phosphorylation. TRPM7 activity influences cytoskeletal dynamics, cell adhesion and migration, and membrane excitability through pathways linked to phosphoinositide signaling, mechanotransduction, and kinase-dependent regulation of downstream effectors. As a central regulator of intracellular magnesium and calcium balance, TRPM7 has been studied in the context of proliferation, stress responses, and metabolic adaptation. Altered TRPM7 function or expression has been associated with neurological injury mechanisms, cardiovascular remodeling, and cancer-relevant signaling states, supporting its utility as a research target in multiple disease models.
LTRPC7 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the TRPM7 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within TRPM7. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt TRPM7 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of TRPM7-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.